The MICRA-HYBRID trial is a prospective, multicenter, randomized controlled study comparing multivessel hybrid coronary revascularization (HCR) as minimally invasive arterial bypass grafting to left-sided coronary targets (LAD and LCx) plus PCI of the RCA versus conventional off-pump coronary artery bypass grafting (OPCAB) via median sternotomy in patients with three-vessel coronary artery disease. The primary goal is to evaluate whether multivessel-HCR provides superior 30-day "textbook" clinical outcomes (mortality, MI, stroke, re-exploration for bleeding, and other complications) while improving perioperative recovery and long-term cardiovascular outcomes.
Patients with three-vessel disease (either angiographic stenoses >70% or a fractional flow reserve value ≤0.80)
Left main diameter stenosis ≥50% or a left main intravascular ultrasound minimal luminal area of ≤4.5 mm2 or fractional flow reserve value ≤0.80 combined with significant CAD of the right coronary artery
Age < 18 or > 85 years
Chronic total occlusion of the RCA
In-stent RCA restenosis
RCA stenosis with high-risk clinical features requiring urgent PCI or surgical revasculari-zation.
Catharina Ziekenhuis Eindhoven
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborator
Eindhoven University of Technology
Collaborator